-
Your selected country is
India
- Change country/language
Old Browser
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
Anti-Cytokeratin Purified
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation And Storage
1. For in vitro diagnostic use.
2. Store the reagent at 2°C to 8°C to maintain stability. Do not use after the expiration date shown on the label.
3. Do not freeze the reagent or expose it to direct light during storage or during incubation with cells. Keep the reagent vial dry.
4. Do not use the reagent if you observe any changes in appearance. Precipitation or discoloration indicates instability or deterioration.
5. The antibody reagent contains sodium azide as a preservative; however, care should be taken to avoid microbial contamination, which may cause erroneous results.
The Becton Dickinson Immunocytometry Systems (BDIS) Anti-Cytokeratin (CAM 5.2) reagent is a murine monoclonal antibody used for qualitative identification of normal cells and malignant cells of epithelial origin in tissue sections (paraffin and frozen) and cytocentrifuge preparations. The clinical interpretation of any staining or its absence should be complemented by morphological studies and proper controls (such as positive, negative, and isotype-matched controls). All tests should be performed by a qualified individual.
Development References (11)
-
A National Committee for Clinical Laboratory Standards. Procedures for the Collection of Diagnostic Blood Specimens by Venipuncture (H3-A3). 1991. (Biology).
-
Cooper D, Schermer A, Sun TT. Biology of disease classification of human epithelia and their neoplasms using monoclonal antibodies to keratins: strategies, applications and limitations. Lab Invest. 1985; 52:243-256. (Biology). View Reference
-
Gatter K, Ralfkiaer E, Skinner J, et al. An immunochemical study of malignant melanoma and its differential diagnosis from other malignant tumors. J Clin Path. 1985; 38:1353-1357. (Biology).
-
Makin C, Bobrow L, Bodmer W. Monoclonal antibody to cytokeratin for use in routine histopathology. J Clin Pathol. 1984; 37(9):975-983. (Biology). View Reference
-
Moll R, Franke W, Schiller D, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors, and cultured cells. Cell. 1982; 31:11-24. (Biology). View Reference
-
National Committee for Clinical Laboratory Standards. Protection of Laboratory Workers from Infectious Disease Transmitted by Blood, Body Fluids, and Tissue: Tentative Guideline (M29-T2). 1991. (Biology).
-
Robbins SL, Cotran RS, Kumar V. Pathologic Basis of Disease. 1984. (Biology).
-
Rose N, Friedman H, JL F, eds.
-
Smedts F, Ramaekers F, Robben H, et al. Changing patterns of keratin expression during progression of cervical intraepithelial neoplasia. Am J Pathol. 1990; 136(3):657-668. (Biology). View Reference
-
Theaker J, Gatter K, Esiri M, et al. Epithelial membrane antigen and cytokeratin expression by meningiomas: an immunohistochemical study. J Clin Pathol. 1986; 39:435-439. (Biology).
-
Wood GS, Warnke RA. Suppression of endogenous avidin-binding activity and its relevance to biotin-avidin detection systems. J Histochem Cytochem. 1981; 29:1196. (Biology).
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.